Drug-related mortality in the United Kingdom: trends, inequalities, and changing substance patterns

Drug-related deaths (DRDs) are a major public health challenge in the UK, but cross-national comparison is complicated by differences in mortality definitions and reporting systems.

We analysed mortality data across the four UK countries to examine trends in mortality burden, geography, age, sex, deprivation, and substance involvement from 2000, using analysis-specific harmonisation to maximise comparability. Joinpoint regression characterised national mortality trends.

DRD rates increased across all countries. Scotland had the highest age-standardised rates throughout, peaking at 27.9 per 100,000 in 2020. The 2001-2023 average annual percentage change (AAPC) was lower in England (2.3%) than in Wales, Scotland and Northern Ireland (4.0-4.6%). Segment-specific APCs showed a decline in England to 2011, followed by an increase; a steeper increase in Wales from 2020; a sharp rise in Scotland during 2015-2019, followed by a decline; and an increase in Northern Ireland to 2021, followed by a non-significant decline. A stepwise deprivation gradient was present in all countries. Opioids remained dominant, while cocaine and gabapentinoid involvement increased across all countries; benzodiazepines were especially prominent in Scotland and Northern Ireland. Novel psychoactive substance involvement increased markedly in Scotland. Specific-substance recording was more complete in Scotland, while polysubstance involvement was prominent but reporting remained patchy and non-harmonised across the UK.

DRDs increased substantially across the UK, with marked geographic and socioeconomic inequalities and increasingly complex substance patterns. A UK-wide perspective highlights shared and country-specific features and supports targeted responses in high-burden places and groups, alongside improved surveillance and more complete mortality data.